賽託生物(300583.SZ)2019年度淨利潤降56.13%至5530.95萬元 擬10派0.52元
格隆匯4月29日丨賽託生物(300583.SZ)發佈2019年年度報告,實現營業收入9.66億元,同比下降8.22%;歸屬於上市公司股東的淨利潤5530.95萬元,同比下降56.13%;歸屬於上市公司股東的扣除非經常性損益的淨利潤4373.35萬元,同比下降57.38%;基本每股收益0.52元,擬每10股派發現金紅利0.52元(含税)。
公司作為製藥企業的原料提供商,自成立以來,致力於應用基因工程技術和微生物轉化技術製造甾體藥物原料,是國內採用生物技術製取甾體藥物原料的重要供應商,在生產甾體藥物原料的同時,佈局呼吸類高端特色原料藥和藥品進口註冊。
公司目前主要產品有:雄烯二酮(AD)、雄二烯二酮(ADD)、9-羥基雄烯二酮(9OH-AD)、羥基黃體酮、四烯物(3TR)、甲羥環氧孕酮(8DM)、開環物等甾體藥物原料。主要被下游企業用於開發的糖皮質激素類、性激素類和蛋白同化激素類等甾體藥物,該類甾體類藥物對機體的發育、生長、代謝和免疫功能起着重要調節作用。
公司目前儲備的呼吸類高端特色原料藥物有丙酸氟替卡鬆(Fluticasone propionate),儲備的製劑有曲安奈德注射液(Triamcinolone Acetonide Injection)、硫糖鋁混懸凝膠(Sucralfate Suspensoid Gel)等多款製劑、抗生素、解毒劑產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.